16 results about "Intermittent hypoxia" patented technology

A system (100) and a method (200) for providing intermittent hypoxia using sequential gas delivery to a subject are disclosed. The method (200) comprises the step (204) of inducing a normoxic end tidal partial pressure of oxygen using a sequential gas delivery system within a first specific number of breaths for a first duration and the step (208) of inducing a hypoxic end tidal partial pressure of oxygen using the sequential gas delivery system within a second number of breaths for a second duration and repeating the steps for a target number of cycles until a therapeutically effective dose of intermittent hypoxia is attained. The sequential gas delivery system (100) may control the end tidal partial pressure of carbon dioxide simultaneously and independently of the end tidal partial pressure of oxygen. The method (200) may be applied in the treatment of a pathological condition in a subject or for improving a health condition of a subject.

FIELD: neurology; psychiatry.SUBSTANCE: used as a non-pharmacological therapy for autism spectrum disorders in children. The method includes a set of procedures: interval hypoxic-hyperoxic training (HHT), hyperbaric oxygenation and ozone therapy. HHT consists of alternating inhalations of a hypoxic mixture with an oxygen content of 9 to 16 vol.% and a hyperoxic mixture with an oxygen content of 32 to 40 vol.% for a total duration of 45-50 minutes under the control of cardiovascular system parameters. Hyperbaric oxygenation is performed in a pressure chamber under a pressure of 1.3 atmospheres of 100% oxygen mixture, flow of 10 liters per minute, for 45 minutes using a mask. Ozone therapy is performed by rectal insufflation with an ozone-oxygen mixture with an ozone concentration of 85 μg / ml in a volume of 20–30 ml or by intravenous administration of a physiological solution enriched with ozone with an ozone concentration of 85 μg / ml at a rate of 200 ml per 100 ml of physiological solution. The procedures are carried out daily for 12 days.EFFECT: method is effective and has a positive impact on the patient’s condition.1 cl, 1 dwg, 3 ex

The invention relates to preparation and application of xenon magnetic lipid bubbles. The xenon magnetic lipid bubble is composed of a xenon core wrapped by a shell layer formed by superparamagnetic iron oxide nanoparticles and phospholipid, has magnetic resonance imaging (MRI) development and magnetic field regulation and control functions, and optionally, the surface of the xenon magnetic lipid bubble is coupled with an LM11A31 ligand to enhance neuronal targeting. In an intermittent hypoxia model, nerve injury can be remarkably improved, and a safe and effective diagnosis and treatment integrated strategy is provided for cognitive impairment related to obstructive sleep apnea.

The application discloses application of NSUN3 in promoting peripheral nerve injury repair. The application adopts intermittent hypoxia induction to promote peripheral nerve injury repair, and for the first time finds that intermittent hypoxia promotes peripheral nerve injury repair by inducing protein expression of a key protein NSUN3. The application discloses that NSUN3 can be used as a brand-new treatment target, and provides a new research angle and theoretical basis for expanding clinical treatment of peripheral nerve injury.

The invention discloses a depression treatment device based on acute intermittent hypoxia adenosine induction. The depression treatment device comprises an intermittent hypoxia generator and a positive pressure breathing mask communicated with the intermittent hypoxia generator. The intermittent low-oxygen generator comprises a nitrogen generator and an air compressor; an output pipeline of the nitrogen generator and an output pipeline of the air compressor are converged and then are connected into a breathing air pipe to be communicated with the positive pressure breathing mask; the nitrogen generator provides constant pressure for an output pipeline of the nitrogen generator, and the nitrogen flow of the output pipeline is controlled through a flow valve. The air compressor provides constant pressure for an output pipeline of the air compressor, and a flow valve is adopted to control the air flow of the output pipeline of the air compressor. The pressure of an output pipeline of the nitrogen generator is the same as that of an output pipeline of the air compressor and is higher than ambient atmospheric pressure; the positive pressure breathing mask is provided with a sealing ring attached to the face of the human body. According to the invention, low oxygen-normal oxygen switching can be realized, adenosine generation is induced, and an exact anti-depression treatment effect is obtained.

A device for intermittent hypoxia-hyperoxia training includes a main chassis; a pressure swing adsorption (PSA) system housed within the chassis, the PSA system configured to generate a hyperoxic gas output and a hypoxic gas output; a buffering reservoir housed within the main chassis, configured to receive the hypoxic gas output from the PSA system; a single user output port; a valve mechanism having a first inlet connected to an output of the buffering reservoir, a second inlet connected to the hyperoxic gas output of the PSA system, and an outlet connected to the single user output port; and a computation unit configured to control the valve mechanism, thereby selecting whether hypoxic gas from the buffering reservoir or hyperoxic gas from the PSA system is delivered to the single user output port.

The invention provides an intermittent anoxic automatic perfusion culture system based on a micro-fluidic chip. The intermittent anoxic automatic perfusion culture system comprises a solution storage device, a first gas supply device, a second gas supply device, a first oxygenation unit, a second oxygenation unit, the micro-fluidic chip and a peristaltic pump, wherein the first gas supply device and the second gas supply device are used for providing normal oxygen gas and anoxic gas respectively; the first oxygenation unit and the second oxygenation unit are connected with the first gas supply device and the second gas supply device respectively; a perfusion culture channel of the micro-fluidic chip comprises a normal oxygen perfusion layer, an anoxic perfusion layer and a cell culture layer; the normal oxygen perfusion layer and the hypoxia perfusion layer are respectively connected with the first oxygenation unit and the second oxygenation unit, the normal oxygen perfusion layer and the hypoxia perfusion layer are respectively connected with the cell culture layer, and the cell culture layer is connected with the solution storage device; the peristaltic pump is connected with the solution storage device and the oxygenation unit, and is used for controlling the cell culture solution to flow into the oxygenation unit for oxygenation, then correspondingly feeding the cell culture solution into the normal oxygen perfusion layer and the anoxic perfusion layer, and controlling the culture solutions in the normal oxygen perfusion layer and the anoxic perfusion layer to alternately perfuse the cell culture layer and then flow back to the solution storage device.

The invention discloses an application of NSUN3 in promotion of peripheral nerve injury repair. Intermittent hypoxia induction is adopted to promote peripheral nerve injury repair, and it is found for the first time that intermittent hypoxia affects peripheral nerve injury repair by inducing lactylation of key protein NSUN3. The NSUN3 disclosed by the invention can be used as a brand-new treatment target, and a new research angle and a theoretical basis are provided for expanding clinical treatment of peripheral nerve injury.

The invention discloses application of GANT61 in preparation of a medicine for preventing and / or treating sleep apnea complicated with heart failure. Experiments show that the GANT61 can improve cardiac function reduction induced by intermittent hypoxia combined with angiotensin II, reduce ventricular remodeling and myocardial fibrosis induced by intermittent hypoxia combined with angiotensin II, inhibit the multiplication capacity of cardiac fibroblasts, inhibit differentiation of cardiac fibroblasts induced by intermittent hypoxia to myofibroblasts, improve the cardiac function reduction induced by intermittent hypoxia combined with angiotensin II, and improve the cardiac function reduction induced by intermittent hypoxia combined with angiotensin II. Intermittent hypoxia-induced cardiac fibroblasts are inhibited from secreting extracellular matrixes, and the weight, blood pressure, heart rate and renal functions are not affected.

The application discloses a kind of based on acute intermittent hypoxia adenosine induction depression treatment device, including intermittent hypoxia generator and with its communication positive pressure breathing mask;The intermittent hypoxia generator includes nitrogen generator, air compressor;The output line of the nitrogen generator is merged with the output line of the air compressor and then connected to breathing air pipe, and the positive pressure breathing mask is communicated;The nitrogen generator provides constant pressure for its output line, and the nitrogen flow of its output line is controlled using flow valve;The air compressor provides constant pressure for its output line, and the air flow of its output line is controlled using flow valve;The output line pressure of the nitrogen generator is the same as the output line pressure of the air compressor and higher than ambient atmospheric pressure;The positive pressure breathing mask has sealing ring that fits human face.The present application can realize low oxygen-normal oxygen switching, induce adenosine generation, and obtain exact antidepressant treatment effect.

A system (100) and a method (200) for providing intermittent hypoxia using sequential gas delivery to a subject are disclosed. The method (200) comprises the step (204) of inducing a normoxic end tidal partial pressure of oxygen using a sequential gas delivery system within a first specific number of breaths for a first duration and the step (208) of inducing a hypoxic end tidal partial pressure of oxygen using the sequential gas delivery system within a second number of breaths for a second duration and repeating the steps for a target number of cycles until a therapeutically effective dose of intermittent hypoxia is attained. The sequential gas delivery system (100) may control the end tidal partial pressure of carbon dioxide simultaneously and independently of the end tidal partial pressure of oxygen. The method (200) may be applied in the treatment of a pathological condition in a subject or for improving a health condition of a subject.

The application discloses a TRPC5 and sleep monitoring index, echocardiogram and inflammation factor correlation analysis method based on blood biochemical detection. According to the correlation analysis method, intermittent hypoxia promotes myocardial cell apoptosis and up-regulates the expression of TRPC5, the myocardial cell apoptosis rate induced by intermittent hypoxia is significantly increased after overexpression of TRPC5, which indicates that TRPC5 promotes the myocardial cell apoptosis induced by intermittent hypoxia IH, promotes myocardial cell inflammatory response and cell pyroptosis, the myocardial cell inflammatory response and cell pyroptosis are aggravated after overexpression of TRPC5, which indicates that TRPC5 may promote the myocardial cell damage induced by IH through the inflammatory response, the role mechanism of TRPC5 in myocardial damage is clarified, and it is indicated that TRPC5 can be a promising target for treating myocardial damage caused by OSAHS.

A device for intermittent hypoxia-hyperoxia training includes a main chassis; a pressure swing adsorption (PSA) system housed within the chassis, the PSA system configured to generate a hyperoxic gas output and a hypoxic gas output; a buffering reservoir housed within the main chassis, configured to receive the hypoxic gas output from the PSA system; a single user output port; a valve mechanism having a first inlet connected to an output of the buffering reservoir, a second inlet connected to the hyperoxic gas output of the PSA system, and an outlet connected to the single user output port; and a computation unit configured to control the valve mechanism, thereby selecting whether hypoxic gas from the buffering reservoir or hyperoxic gas from the PSA system is delivered to the single user output port.

This invention discloses the application of the long-chain fatty acid 12-HHT in sleep apnea complicated with hypertension, belonging to the field of biomedicine. Specifically, 12-HHT is used as a diagnostic or drug target to prepare drugs or reagents for the diagnosis or treatment of sleep apnea complicated with hypertension. The molecular formula of 12-HHT is C2. 17 H 28 O3, with the structural formula shown, refers to obstructive sleep apnea-hypopnea syndrome combined with hypertension. The drug can be a targeted therapy, with 12-HHT as the target. This invention, using an intermittent hypoxic endothelial cell model, found that 12-HHT can inhibit excessive proliferation and migration of endothelial cells induced by intermittent hypoxia, thus exerting a therapeutic effect. This demonstrates its effectiveness as an intervention target for OSAHS combined with hypertension, providing a novel potential therapeutic drug for this type of patient.

The invention provides a low-oxygen-resistant variety breeding method for trachinotus ovatus, and relates to the technical field of low-oxygen-resistant variety breeding for trachinotus ovatus, and the method specifically comprises the following steps: carrying out a low-oxygen stress test on a trachinotus ovatus group, determining a dissolved oxygen value and survival time of a suffocation point, screening phenotype-resistant extreme individuals, and obtaining genotype data of the individuals; identifying a target SNP marker significantly related to the hypoxia resistance character through whole genome association analysis; performing genotyping on the backup parents by using the target SNP, calculating a hypoxia resistance evaluation index, and screening excellent parents to establish a core breeding population; filial generations are obtained through breeding, and candidate groups are screened in combination with favorable allele detection and genome estimation breeding values; and in combination with an intermittent hypoxia stress test performed on the candidate group, calculating a comprehensive growth expression index based on the body length and the body weight, and selecting a final hypoxia-resistant trachinotus ovatus variety. According to the invention, efficient and accurate hypoxia-resistant character breeding can be realized.

The application discloses a data-driven plateau hypoxia injury risk measurement system and method, belongs to the technical field of human hypoxia injury risk assessment, and comprises an intermittent hypoxia training module, a wearable physiological signal collection module, a hypoxia cabin test module, a centralized data storage and learning module, an edge data processing and hypoxia injury risk assessment module and a communication and transmission module.The data-driven plateau hypoxia injury risk measurement system and method adopt the above structure, realize the function of low-cost, rapid and dynamic assessment of the hypoxia injury risk of subjects, and can assess the hypoxia injury risk of subjects in a safer, faster and lower-cost manner without actual entry of the subjects into a plateau environment.